In mid-April, President Trump issued an executive order to set aside funding and loosen the bureaucratic process at the FDA to fast-track psychedelic therapy research. One obscure psychedelic got a particularly bright spotlight: ibogaine. Originating from the root bark of the iboga plant of central Africa, the psychedelic has shown promise for curbing opioid addiction and treating PTSD. But it also can be risky to take, and hasn’t made it to the medical mainstream like psilocybin or ketamine. So what’s the story with this drug? Joining Host Flora Lichtman to talk about its history is neurologist and pharmacologist Deborah Mash, who secured the first FDA approval for clinical trials involving ibogaine in the 1990s. And to tell us how it fits in with the growing interest in medical psychedelics is Jane Hu, journalist for The Microdose newsletter. (Disclosure: Deborah Mash is founder and CEO of a company that’s developing a therapeutic drug based on ibogaine.) Guests: Jane C. Hu is a journalist for the psychedelic science newsletter The Microdose, based in Seattle, WA. Dr. Deborah Mash is professor emeritus of neurology and molecular and cellular pharmacology at the University of Miami School of Medicine. She is the also founder and CEO of DemeRx. Other episodes you may enjoy: How One Gene Affects Alzheimer’s Risk Is This PTSD Treatment Too Good To Be True? Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.